Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Marketing Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Marketing
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Upcoming events – Cancer readouts for Merck & Co and Seattle
Upcoming events – Cancer readouts for Merck & Co and Seattle
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
Pfizer, Merck KGaA’s Bavencio takes a hit with second ovarian cancer failure
Pfizer, Merck KGaA’s Bavencio takes a hit with second ovarian cancer failure
Merck takes a back seat on CAR-T, handing assets to Intrexon
Merck takes a back seat on CAR-T, handing assets to Intrexon
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Merck KGaA and Pfizer’s Checkpoint Inhibitor Fails in Late-Stage Ovarian Cancer Study
Merck KGaA and Pfizer’s Checkpoint Inhibitor Fails in Late-Stage Ovarian Cancer Study
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Επιστροφή στα κέρδη «βλέπει» το 2019 η φαρμακευτική Merck KGaA
Επιστροφή στα κέρδη «βλέπει» το 2019 η φαρμακευτική Merck KGaA
The top 10 drugmakers of 2024
The top 10 drugmakers of 2024
Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up … Continue Reading Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Pfizer, Merck Combination Therapy Shows Significant Improvement in Phase III
Pfizer, Merck Combination Therapy Shows Significant Improvement in Phase III
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
